• InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function
• With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency
• InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families

InMed Pharmaceuticals (NASDAQ:INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids” (https://cnw.fm/4mWW0).

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.